The 2020 Nicotine Addiction pipeline report presents a comprehensive overview of the research and development of Nicotine Addiction drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: 14 drugs in Pre-clinical phase, three drugs in Phase 1 and one drug in Phase 2.
As of February 2020, the Nicotine Addiction pipeline remains robust with 18 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Nicotine Addiction treatment. Diverse types of targeted therapies are being explored through clinical trials including Alpha3 Beta4 nAChR partial agonist; Alpha3 beta4 nicotinic receptor antagonist; Cannabinoid receptor antagonist; Cannabinoid receptor modulators; glucocorticoid receptor antagonist; metabotropic glutamate receptor 2 (mGlu2) agonist; Nicotinic antagonists; opioid delta, mu and kappa receptor agonist; orexin-1 receptor antagonist; PDE7 inhibitor; peroxisome proliferator-activated gamma receptor agonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Nicotine Addiction drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
Publisher Expertise
The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
Scope:
Nicotine Addiction pipeline companies included in the report are: Antidote Therapeutics Inc, Assuage Pharmaceuticals Inc, Astraea Therapeutics LLC, Camino Pharma LLC, Cessation Therapeutics LLC, Chronos Therapeutics Ltd, CV Sciences Inc, DemeRx Inc, Indivior Plc, MAKScientific LLC, Omeros Corp, Palisades Therapeutics, Savant HWP Inc, Sosei Heptares, Tria Bioscience Corp.
Nicotine Addiction pipeline drugs profiled in the report include: ATI-1013, ATI-3009, AP-202, AT-1001, SBP-0069330, Biologics for Nicotine Addiction, CTDP-002, CVSI-007 (cannabidiol + nicotine), Noribogaine, C4X3256, AM4113, AM6527, OMS405, OMS527, PT150, 18-Methoxycoronaridine (18-MC), orexin 1 antagonist for Nicotine Addiction, Vaccine for Nicotine Addiction.
As of February 2020, the Nicotine Addiction pipeline remains robust with 18 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Nicotine Addiction treatment. Diverse types of targeted therapies are being explored through clinical trials including Alpha3 Beta4 nAChR partial agonist; Alpha3 beta4 nicotinic receptor antagonist; Cannabinoid receptor antagonist; Cannabinoid receptor modulators; glucocorticoid receptor antagonist; metabotropic glutamate receptor 2 (mGlu2) agonist; Nicotinic antagonists; opioid delta, mu and kappa receptor agonist; orexin-1 receptor antagonist; PDE7 inhibitor; peroxisome proliferator-activated gamma receptor agonist.
The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Nicotine Addiction drug development history, latest news, and other developments.
It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.
Publisher Expertise
The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.
Scope:
- The report scope comprises of both pre-clinical phase and clinical phase development drugs for Nicotine Addiction development
- Nicotine Addiction pipeline compounds and molecules under study by both large scale and small companies are included in the report
- Nicotine Addiction pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
- Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
- Further, orphan drug status, fast track designation, different grants awarded and special status for Nicotine Addiction pipeline candidates included
- Business overview and snapshot of all companies involved in Nicotine Addiction pipeline are included
- Latest market and pipeline developments are provided in the report
Nicotine Addiction pipeline companies included in the report are: Antidote Therapeutics Inc, Assuage Pharmaceuticals Inc, Astraea Therapeutics LLC, Camino Pharma LLC, Cessation Therapeutics LLC, Chronos Therapeutics Ltd, CV Sciences Inc, DemeRx Inc, Indivior Plc, MAKScientific LLC, Omeros Corp, Palisades Therapeutics, Savant HWP Inc, Sosei Heptares, Tria Bioscience Corp.
Nicotine Addiction pipeline drugs profiled in the report include: ATI-1013, ATI-3009, AP-202, AT-1001, SBP-0069330, Biologics for Nicotine Addiction, CTDP-002, CVSI-007 (cannabidiol + nicotine), Noribogaine, C4X3256, AM4113, AM6527, OMS405, OMS527, PT150, 18-Methoxycoronaridine (18-MC), orexin 1 antagonist for Nicotine Addiction, Vaccine for Nicotine Addiction.
Table of Contents
1. Table of Contents
2. Executive Summary
3. Companies Active in Pipeline Development
4. Active Pipeline Drug Details, 2020
6. Appendix
Companies Mentioned
- Antidote Therapeutics Inc
- Assuage Pharmaceuticals Inc
- Astraea Therapeutics LLC
- Camino Pharma LLC
- Cessation Therapeutics LLC
- Chronos Therapeutics Ltd
- CV Sciences Inc
- DemeRx Inc
- Indivior Plc
- MAKScientific LLC
- Omeros Corp
- Palisades Therapeutics
- Savant HWP Inc
- Sosei Heptares
- Tria Bioscience Corp
